NK cells are effector innate lymphoid cells (ILCs) that do not require antigen-specific priming. NK cells are not only killer cells that help to suppress tumors, but also are involved in the generation and maintenance of adaptive immune responses.  The process of antibody-dependent cell-mediated cytotoxicity (ADCC) makes use of innate immune cells which provide antitumor …Read More >

Rat tumor models are a better mimic of human pathology compared to mice. The tumor stroma component of rats is about 1.5 to 2-fold higher relative to mice. Rats are considered an ideal model for preclinical efficacy studies, as they are physiologically, metabolically, and genetically more similar to humans.  To support drug discovery teams, WuXi …Read More >

Antibody‒drug conjugates (ADCs), which combine the advantages of monoclonal antibodies with precise targeting and payloads, show great potential as cancer therapies.  However, primary and secondary resistance is frequently observed, and development of next generation ADCs necessitates the establishment of resistant tumor models.  One mechanism of resistance involves efflux of the ADC payload by the transporter …Read More >

The EML4-ALK fusion gene occurs in approximately 5% of non-small-cell lung cancers (NSCLCs), making this oncogene an important drug target.  The development of ALK tyrosine kinase inhibitors (ALK-TKIs) has been a major advance in treating NSCLC with this fusion gene, but acquired resistance to ALK-TKIs ultimately limits their use.  To support the development of next-generation …Read More >

High-dimensional (HD) flow cytometry allows researchers to perform deep phenotyping of immune cells at the single cell level with increased accuracy and sensitivity.  This technology enables complex pathway characterization and data integration for the identification of biomarkers used in immunotherapy.  WuXi AppTec offers a comprehensive panel of HD flow cytometry services, with more than 100 …Read More >

To support antitumor efficacy testing and address the challenges of clinical translatability, WuXi AppTec offers extensive panels of immune-avatar humanized mouse models. Our platform includes hPBMC, hHSC, and hNK humanized models with enabling studies from our platform of over 1,700 CDX and PDX models. These well-established models cover multiple cancer types, including breast, lung, liver, …Read More >

Patient-derived xenografts (PDXs) represent a powerful platform for cancer drug screening and biomarker discovery and are considered the gold standard of in vivo models for their proven clinical relevance to human disease. WuXi AppTec offers a comprehensive platform of more than 1,400 well-annotated PDXs across 30 cancer types. We also provide expanded in vitro, ex …Read More >

The cumulative impact of chronic inflammation in patients with inflammatory bowel disease (IBD) predisposes them to the development of IBD-associated colorectal cancer. To support drug discovery research in this area, WuXi AppTec has developed a colitis-associated cancer mouse model to reflect the human colon’s carcinogenesis pattern derived from inflammation. Key features of this model include …Read More >

Tumors and anti-tumor therapies may cause diverse systemic complications. Treatment of these complications is essential in optimizing quality of life and improving the clinical value of cancer therapies. WuXi AppTec offers well-established in vivo tumor complication-related models in a translationally relevant platform to support drug discovery teams. Our panel includes cancer models representing cachexia, diarrhea, …Read More >